| Is inappropriate medication use a major cause of adverse drug reactions in the elderly? ML Laroche, JP Charmes, Y Nouaille, N Picard, L Merle British journal of clinical pharmacology 63 (2), 177-186, 2007 | 450 | 2007 |
| Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism N Picard, D Ratanasavanh, A Prémaud, Y Le Meur, P Marquet Drug metabolism and disposition 33 (1), 139-146, 2005 | 332 | 2005 |
| The role of organic anion–transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics N Picard, SW Yee, JB Woillard, Y Lebranchu, Y Le Meur, KM Giacomini, ... Clinical Pharmacology & Therapeutics 87 (1), 100-108, 2010 | 190 | 2010 |
| In vitro metabolism study of buprenorphine: evidence for new metabolic pathways N Picard, T Cresteil, N Djebli, P Marquet Drug metabolism and disposition 33 (5), 689-695, 2005 | 168 | 2005 |
| Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients K Benkali, A Prémaud, N Picard, JP Rérolle, O Toupance, G Hoizey, ... Clinical pharmacokinetics 48, 805-816, 2009 | 161 | 2009 |
| UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice MC Etienne‐Grimaldi, JC Boyer, F Thomas, S Quaranta, N Picard, ... Fundamental & Clinical Pharmacology 29 (3), 219-237, 2015 | 116 | 2015 |
| Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a … K Rouguieg, N Picard, FL Sauvage, JM Gaulier, P Marquet Drug metabolism and disposition 38 (1), 40-45, 2010 | 111 | 2010 |
| Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5 N Picard, T Cresteil, A Prémaud, P Marquet Therapeutic drug monitoring 26 (6), 600-608, 2004 | 94 | 2004 |
| Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse A Al Saabi, D Allorge, FL Sauvage, G Tournel, J Gaulier, P Marquet, ... Drug Metabolism and Disposition 41 (3), 568-574, 2013 | 88 | 2013 |
| Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients N Djebli, N Picard, JP Rérolle, Y Le Meur, P Marquet Pharmacogenetics and genomics 17 (5), 321-330, 2007 | 84 | 2007 |
| Donor P‐gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long‐term follow‐up JB Woillard, JP Rerolle, N Picard, A Rousseau, A Guillaudeau, ... Clinical Pharmacology & Therapeutics 88 (1), 95-100, 2010 | 83 | 2010 |
| Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil O Gensburger, RHN Van Schaik, N Picard, Y Le Meur, A Rousseau, ... Pharmacogenetics and genomics 20 (9), 537-543, 2010 | 77 | 2010 |
| CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients N Picard, K Rouguieg-Malki, N Kamar, L Rostaing, P Marquet Transplantation 91 (6), 652-656, 2011 | 74 | 2011 |
| Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs N Picard, S Bergan, P Marquet, T Van Gelder, P Wallemacq, ... Therapeutic drug monitoring 38, S57-S69, 2016 | 71 | 2016 |
| A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients N Picard, A Prémaud, A Rousseau, Y Le Meur, P Marquet British journal of clinical pharmacology 62 (4), 477-484, 2006 | 69 | 2006 |
| Risk of diarrhoea in a long‐term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele JB Woillard, JP Rerolle, N Picard, A Rousseau, M Drouet, E Munteanu, ... British journal of clinical pharmacology 69 (6), 675-683, 2010 | 65 | 2010 |
| General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints FL Sauvage, N Picard, F Saint‐Marcoux, JM Gaulier, G Lachâtre, ... Journal of separation science 32 (18), 3074-3083, 2009 | 56 | 2009 |
| Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5 N Picard, N Djebli, FL Sauvage, P Marquet Drug metabolism and disposition 35 (3), 350-355, 2007 | 56 | 2007 |
| The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation N Picard, P Marquet Expert opinion on drug metabolism & toxicology 7 (6), 731-743, 2011 | 45 | 2011 |
| Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients JB Woillard, N Kamar, S Coste, L Rostaing, P Marquet, N Picard Clinical Chemistry 59 (12), 1761-1769, 2013 | 41 | 2013 |
